The article discusses the potential of Pfizer (PFE) as a 'millionaire maker' stock. It suggests that due to Pfizer's large market capitalization and the nature of big pharma, the stock is unlikely to deliver massive returns quickly. Investors would need to commit significant capital and hold the stock long-term, reinvesting dividends, to potentially become millionaires.